Nasdaq · Healthcare
IRIDEX CORP (IRIX)
As-reported financials and recent SEC filings for IRIDEX CORP, latest fiscal period FY2026. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$52.7M
Net income
$-4.4M
Net margin
-8.4%
Diluted EPS
$-0.26
ROE
-90.1%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2026 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $52.7M | $48.7M | $51.9M | $57.0M | $53.9M |
| Gross profit | $19.2M | $19.5M | $21.8M | $25.4M | $22.8M |
| Operating income | $-2.6M | $-8.3M | $-10.0M | $-7.5M | $-7.5M |
| Net income | $-4.4M | $-8.9M | $-9.6M | $-7.5M | $-5.2M |
| Diluted EPS | $-0.26 | $-0.54 | $-0.59 | $-0.47 | $-0.34 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-06-18
View on EDGAR →42026-06-16
View on EDGAR →42026-06-16
View on EDGAR →42026-06-15
View on EDGAR →42026-06-12
View on EDGAR →42026-06-09
View on EDGAR →42026-06-08
View on EDGAR →42026-06-03
View on EDGAR →Largest Healthcare peers
Go deeper on IRIX
Search IRIDEX CORP’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.